Why the study?
PPCI is first-line treatment for acute STEMI, but evidence of its benefit in the elderly is sparse.
Primary percutaneous coronary intervention in STEMI patients aged 85 years or older yields a median survival of 2.55 years, suggesting advanced age alone should not preclude this treatment.
Answers are grounded in this paper and cite their sources.
May support PPCI consideration in selected ≥85-year STEMI patients; leaves open optimal selection and comparative effectiveness.
BACKGROUND: Primary percutaneous coronary intervention (PPCI) is the first-line treatment for acute ST-elevation myocardial infarction (STEMI). Evidence of benefit from PPCI in the elderly is sparse. Our aim was to evaluate survival outcomes in patients aged ≥85 years who undergo PPCI for STEMI. METHODS: Clinical data were collected retrospectively on all patients aged ≥85 years who were referred and accepted for PPCI to our centre between 2013 and 2018. RESULTS: One hundred and forty-three patients received PPCI. Median hospital stay was seven days. One hundred and thirty-one patients survived admission. One-year mortality was 33.5%. Age and baseline renal function were independent predictors of one-year mortality. Median survival was 2.55 years. CONCLUSION: Advanced age alone should not be used as an exclusion criterion for PPCI; rather, a personalised approach that takes into account all clinically relevant patient factors should guide PCI decision-making. Our findings suggest that PPCI as first-line treatment for STEMI in the very old should be considered routinely.
No takes yet. Share an insight, caveat, or question.
Aubinière-Robb et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: